The role of Sym004, a novel EGFR antibody mixture, in patients with refractory colorectal cancer

Colorectal cancer is the fourth most frequently diagnosed cancer in the United States and a major cause of mortality throughout the world. It is estimated that in 2015, 132,700 new patients have been diagnosed with colorectal cancer in the United States and 49,700 have died from the disease (1). Even though recent advances in the treatment of metastatic colorectal cancer have significantly prolonged clinical outcome, long-term survival does not exceed 10%. Ongoing research has focused on targeted therapies in order to further increase survival rates.